1. Inhalt
  2. Navigation
  3. Weitere Inhalte
  4. Metanavigation
  5. Suche
  6. Choose from 30 Languages


Bayer Wins Latest Round in Lipobay Fight

German pharmaceutical conglomerate Bayer has won the latest round in the legal fight over the controversial cholesterol drug Lipobay, or Baycol as it is known in the US, after a federal judge in the U.S. District Court in Minneapolis denied a request for national class-action litigation against the company on Wednesday. Lawyers representing the plaintiffs opposing the drug, which has been linked to more than 100 deaths and side-effects such as muscle wasting before it was withdrawn from the market in 2001, sought to fight Bayer in three class group cases: those that suffered injury from the drug, those who needed medical monitoring to inhibit future illness caused by the drug, and those who should get a refund for the drug. The judge ruled that were too many complexities to fold into one national lawsuit. The company has attempted to settle cases tied to the drug but has fought vigorously against what it says are the many unsubstantiated claims that have been brought to court.